GSK chief executive, Andrew Witty, told reporters that as a standalone company, ViiV Healthcare would be among the top 40 companies in London's FTSE 100 index, outranking such household names as retailer Marks and Spencer.
Analysts at Jefferies said they valued the HIV and AIDS division at about GBP17bn. Announcing third-quarter results, GSK said that the new restructuring programme would save GBP1bn in annual costs within three years, with half of that achieved by 2016.
(EUR1 = GBP0.79)
Perrigo to acquire United States rights for Entocort from AstraZeneca
US FDA approves Boehringer Ingelheim's Pradaxa
Phase II clinical trial for potential treatment of androgenetic alopecia completed by Samumed
Life Sciences Partners collaborates on immuno-oncology with Bristol-Myers Squibb
Arsanis initiates first cohort in Phase one clinical trial of ASN100
Impax introduces generic Avodart (Dutasteride) Capsules, 0.5 mg
Mylan unveils generic FazaClo orally disintegrating tablets for treating schizophrenia